ArticleTrials2024

Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).

Lillian Streichart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.